Keros Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Keros Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Lexington
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KROS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001664710
- EIN
- 81-1173868
Board of directors
-
Alpna Seth · DirectorSince 2023
-
Anne Prener · DirectorSince 2026
- Since 2023
-
Charles W. Newton · DirectorSince 2026
-
Jasbir Seehra · Director · CHIEF EXECUTIVE OFFICERSince 2023
- Since 2024
-
Julius Knowles · DirectorSince 2023
-
Mary Ann Gray · DirectorSince 2023
-
Nima Farzan · DirectorSince 2023
-
Ran Nussbaum · DirectorSince 2023
-
Tomer Kariv · DirectorSince 2023
Chief executives
Jasbir Seehra
· CHIEF EXECUTIVE OFFICER
Dates unknown
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.5%
Board connections
9 of this board's directors also sit on 21 other boards.
- via Carl L. Gordon and Mary Ann Gray
- via Carl L. Gordon
- via Carl L. Gordon
- via Jean Jacques Bienaime
- via Alpna Seth
- via Jean Jacques Bienaime
- via Carl L. Gordon
- via Charles W. Newton
- via Anne Prener
- via Alpna Seth
- via Carl L. Gordon
- via Tomer Kariv
- via Jean Jacques Bienaime
- via Jean Jacques Bienaime
- via Ran Nussbaum
- via Nima Farzan
- via Carl L. Gordon
- via Charles W. Newton
- via Mary Ann Gray
- via Carl L. Gordon
- via Ran Nussbaum
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $75,770
- 6 purchases by 1 insider
- Sold, last 12 months
- $181,157,511
- 19 sales by 11 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2026 | Cho Esther Officer (Chief Legal Officer) | Open-market sale | −4,485 | $10.29 | $46,151 |
| Aug 18, 2026 | Charles W. Newton Director | Open-market sale | −551 | $10.30 | $5,675 |
| Aug 18, 2026 | Lerner Lorena Raquel Officer (Chief Scientific Officer) | Open-market sale | −3,568 | $10.29 | $36,715 |
| Aug 18, 2026 | Tanini Annita Officer (Corp. Controller & VP, Finance) | Open-market sale | −1,224 | $10.29 | $12,595 |
| Aug 17, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +1,000 | $10.27 | $10,270 |
| Jul 15, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +1,000 | $10.61 | $10,610 |
| Jul 1, 2026 | Anne Prener Director | Grant or award | +13,786 | — | — |
| Jun 15, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +1,000 | $10.19 | $10,190 |
| Jun 11, 2026 | Charles W. Newton Director | Open-market sale | −550 | $10.04 | $5,522 |
| Jun 4, 2026 | Nima Farzan Director | Open-market sale | −2,625 | $10.73 | $28,166 |
| Jun 4, 2026 | Julius Knowles Director | Open-market sale | −2,625 | $10.73 | $28,166 |
| Jun 4, 2026 | Alpna Seth Director | Open-market sale | −2,625 | $10.72 | $28,140 |
| Jun 3, 2026 | Alpna Seth Director | Grant or award | +7,142 | — | — |
| Jun 3, 2026 | Julius Knowles Director | Grant or award | +7,142 | — | — |
| Jun 3, 2026 | Mary Ann Gray Director | Grant or award | +7,142 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.